Elaprase (idursulfase) is Associate in Nursing IV infusion wont to treat a number of the symptoms of a genetic condition known as Hunter’s syndrome, additionally known as hereditary condition (MYOO-koe-pol-ee-SAK-a-rye-DOE-sis).

Hunter syndrome could be a upset during which the body lacks the protein required to interrupt down sure sugars and proteins. These substances will build up within the body, inflicting enlarged organs, abnormal bone structure, changes in countenance, respiration issues, heart issues, vision loss, and changes in mental or physical talents.

Elaprase might improve walking ability in individuals with this condition. However, this medication isn’t a cure for Hunter syndrome.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Elaprase
  • Some side effects may occur during the Elaprase infusion, or up to 24 hours afterward. Get emergency medical help if you have any of these signs of an allergic reaction to Elaprase: feeling like you might pass out; hives; trouble breathing, seizure (convulsions); swelling of your face, lips, tongue, or throat.

    It may still be possible for you to receive Elaprase even after you have had a reaction to it. There are other medications that can be given to you before your infusion to help prevent symptoms of a reaction.

    Common Elaprase side effects may include:

    vomiting, diarrhea;
    headache;
    fever, cough;
    itching, mild skin rash; or
    flushing (warmth, redness, or tingly feeling).
  • Usual Adult Dose for Mucopolysaccharidosis Type II: 0.5 mg/kg via IV infusion once a week Comments: -Has been shown to improve walking capacity Approved indication: For patients with Hunter syndrome (mucopolysaccharidosis II [MPS II]) Usual Pediatric Dose for Mucopolysaccharidosis Type II: 16 months or older: 0.5 mg/kg via IV infusion once a week Comments: -Has been shown to improve walking capacity in patients 5 years and older -No data available to show improvement in disease-related symptoms or long-term clinical outcome in patients 16 months to 5 years; however, spleen volume reduced similarly to that of patients 5 years and o